Adjuvance Technologies
Chemicals & Related Products · Nebraska, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1225 L St Ste 600, Lincoln, Nebraska, 68...Phone Number
(402) 817-5050Revenue
$5.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Adjuvance Technologies
About Adjuvance Technologies: Adjuvance Technologies is a privately-held, clinical-stage biopharmaceutical company dedicated to making vaccines better through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing. Adjuvance creates and manufactures next generation proprietary adjuvants as the foundation of its vaccine pipeline and for other developers through licensing partnerships. The company's lead vaccine candidate against shingles aims to provide a better patient experience including improved tolerability for the recipient and the same protection against disease. Headquartered in Lincoln, Nebraska, the company has received grant funding from the National Institutes of Health (NIH) and closed a Series A investment by Morningside Venture Investments.Explore more
Adjuvance Technologies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Adjuvance Technologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Adjuvance Technologies launches new products
Funding: Get notified immidiatlly once Adjuvance Technologies has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Adjuvance Technologies had a recent Job posting/layoffs
Adjuvance Technologies, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Adjuvance Technologies has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Adjuvance Technologies
Earning: See what the market has to say on Adjuvance Technologies recently announced quarterly report
Check out if Adjuvance Technologies is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Adjuvance Technologies as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Adjuvance Technologies is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Adjuvance Technologies is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Adjuvance Technologies.
Adjuvance Technologies financials insights
Gather financial insights about Adjuvance Technologies, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Corporate Investment
$1.5M
Adjuvance Technologies Tech Stack
A closer look at the technologies used by Adjuvance Technologies
See more technologies
Adjuvance Technologies News & Media
Adjuvance Technologies gibt die Erteilung eines US-Patents für halbsynthetische Saponin-Adjuvantien bekannt
LINCOLN, Nebraska--(BUSINESS WIRE)--Adjuvance Technologies Inc., ein privates Biopharmaunternehmen im klinischen Stadium, das Saponin-Adjuvantien und Impfstoffe der nächsten Generation für Infektionskrankheiten und Immunonkologie entwickelt, gab heute die Erteilung des US-Patents Nr. 10.906.926 durch das United States Patent and Trademark Office (USPTO) bekannt. Das Patent bezieht sich auf Triterpensaponin-Analoga, insbesondere auf das Saponin-Adjuvans der nächsten Generation von Adjuvance, TQLAdjuvance Technologies Announces Issuance of U.S. Patent Covering Semi-Synthetic Saponin Adjuvants
LINCOLN, Neb.--(BUSINESS WIRE)-- #adjuvant--USPTO issues patent to Adjuvance and Memorial Sloan Kettering Cancer Center covering TQL-1055 adjuvant for multiple uses including shingles vaccine.Adjuvance Technologies gibt erste klinische Ergebnisse für sein Saponin-Adjuvans der nächsten Generation bekannt
LINCOLN, Nebraska--(BUSINESS WIRE)--Adjuvance Technologies Inc., ein privates Biopharmaunternehmen im klinischen Stadium, das Saponin-Adjuvantien und Impfstoffe für Infektionskrankheiten und Immunonkologie entwickelt, hat bekannt gegeben, dass sein Adjuvans TQL-1055 in Verbindung mit einem gleichzeitig verabreichten Impfstoff gegen Keuchhusten sicher und gut verträglich war. Dies ist die erste klinische Studie mit einem Kandidaten aus dem Adjuvans- und Impfstoffportfolio des Unternehmens. „DieAdjuvance Technologies Announces First Clinical Results of its Next-generation Saponin Adjuvant
LINCOLN, Neb.--(BUSINESS WIRE)-- #IDweek--Adjuvance Technologies Announces First Clinical Results of its Next-generation Saponin Adjuvant
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Adjuvance Technologies
Sign Up For FreeTo access detailed company insights
About Adjuvance Technologies: Adjuvance Technologies is a privately-held, clinical-stage biopharmaceutical company dedicated to making vaccines better through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing. Adjuvance creates and manufactures next generation proprietary adjuvants as the foundation of its vaccine... Read More
